Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.
about
Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic EvidenceCost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1A Revolution in Treatment for Hepatitis C Infection: Mitigating the Budgetary Impact.Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic ResponseAccessibility to Oral Antiviral Therapy for Patients with Chronic Hepatitis C in the United StatesCancer Drug Pricing and Reimbursement: Lessons for the United States From Around the World.Healthcare Costs Related to Treatment of Hepatocellular Carcinoma Among Veterans With Cirrhosis in the United States.Model-based projection of health and economic effects of screening for hepatitis C in Canada.Mobilising a global response to hepatitis: Lessons learned from the HIV movement.Current challenges and future directions for liver transplantation.Pre-clinical and clinical investigations of metabolic zonation in liver diseases: The potential of microphysiology systems.Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study."Tweak Your Order Set!" Implementation of Modified Laboratory Order Set Improves Hepatitis C Virus Screening Rates in People Living With Human Immunodeficiency Virus.Real world experience with pegylated interferon and ribavirin in hepatitis C genotype 1 population with favourable IL28B polymorphism.The burden of hepatitis C to the United States Medicare system in 2009: Descriptive and economic characteristics.Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis.Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States.Long-term disease and economic outcomes of prior authorization criteria for Hepatitis C treatment in Pennsylvania Medicaid.Uptake of hepatitis C screening, characteristics of patients tested, and intervention costs in the BEST-C study.Prevention of progression to cirrhosis in hepatitis C with fibrosis: effectiveness and cost effectiveness of sequential therapy with new direct-acting anti-virals.Community-based real-world treatment outcomes of sofosbuvir/ledipasvir in Asians with chronic hepatitis C virus genotype 6 in the United States.Chronic hepatitis C virus (HCV) burden in Rhode Island: modelling treatment scale-up and elimination.Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease.The cost and value of cancer drugs - are new innovations outpacing our ability to pay?A global comparison of the cost of patented cancer drugs in relation to global differences in wealth.Medicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis C.Cost-Effectiveness of Treatments for Genotype 1 Hepatitis C Virus Infection in non-VA and VA Populations.CT predicts liver fibrosis: Prospective evaluation of morphology- and attenuation-based quantitative scores in routine portal venous abdominal scansA Guide to the Economics of Hepatitis C Virus Cure in 2017Population Health and Cost-Effectiveness Implications of a "Treat All" Recommendation for HCV: A Review of the Model-Based Evidence
P2860
Q28072257-44A65A40-04D9-4BD7-9BB1-0DBE5DACD655Q33629561-80C990FE-1507-4A91-8159-2908924B81E0Q36034709-7EC86A26-176F-4A48-B091-4A3C0C726786Q36240269-73064C68-2C03-416D-AA00-98D9EB001B57Q37018850-9FF1D2E4-D218-4635-A8E7-7D9662175D8DQ37162297-3686E07A-843D-497E-A54E-6A8EA41B1AE1Q38399579-3295EE7B-EF6E-4A67-9F88-2D4011A8D035Q38603224-26705946-B564-43AD-9991-188EBE99AEE7Q38810895-9D7D4D33-9BA7-4CEC-A4E7-9E117B17F964Q38820685-173D2B9F-8912-47AF-9262-63B98B0719CDQ39280379-72B2C630-5B22-4200-93AF-B244B0715454Q39481949-97D3E9DF-4E88-4BA0-A986-551F9286639BQ40065615-F7121FBA-D277-45D0-B075-50601FF8784CQ40065692-5283F39C-31CA-4B37-8A16-355449B2B055Q40168920-37A7A3F8-5143-4A64-BF53-2821FAC559EBQ40302226-342F6782-D866-4B1A-B48C-C2B84DF00E16Q40345258-521EE711-FB2B-44F5-B347-FF2F61B0EFE2Q40417472-069D9E35-3566-414A-BAB9-4CA280AB50CFQ40524477-E1AE3A59-A269-4E90-BAED-BC44902D640CQ40562865-876645B1-F751-4E88-A8AD-A822774623E6Q40563566-319159C6-B0BB-49F7-92A0-E54F373C3588Q40588090-F31923B3-5FFF-40C1-84B2-281C6FFC92F4Q42048758-E24A6A80-30FF-4401-AC39-9F0D221BDA54Q42392412-5FA87621-665B-4F69-8C6C-4A4549F3AF7EQ42700925-B3533BD0-F1E7-4FA7-9D19-3DDD47CC89D6Q53381076-889D87EE-E5BD-451B-AA1E-46CF0C4D3A97Q54984374-0F42ABC3-07DF-43D8-8210-5A71497F7B1AQ56526856-0731210F-E32B-435F-A64E-A93541CED3B3Q56654943-B570461E-2286-42D1-ACCF-005F128D08C2Q57145115-59078A5C-10C6-437B-B18E-12FA3B886427
P2860
Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Cost-effectiveness of Early Tr ...... US Treatment-Naive Population.
@en
Cost-effectiveness of Early Tr ...... US Treatment-Naive Population.
@nl
type
label
Cost-effectiveness of Early Tr ...... US Treatment-Naive Population.
@en
Cost-effectiveness of Early Tr ...... US Treatment-Naive Population.
@nl
prefLabel
Cost-effectiveness of Early Tr ...... US Treatment-Naive Population.
@en
Cost-effectiveness of Early Tr ...... US Treatment-Naive Population.
@nl
P2093
P2860
P1476
Cost-effectiveness of Early Tr ...... US Treatment-Naive Population.
@en
P2093
Daniel A Ollendorf
Elliot A Marseille
Harinder S Chahal
James G Kahn
Jeffrey A Tice
Rena K Fox
Steve D Pearson
P2860
P356
10.1001/JAMAINTERNMED.2015.6011
P577
2015-11-23T00:00:00Z